• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Enzalutamide treatment increases median overall survival in non-metastatic prostate cancer

byHarsh ShahandDeepti Shroff Karhade
June 5, 2020
in Oncology, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate cancer.

2. Adverse events for enzalutamide and androgen-deprivation therapy were shown to be consistent with the established safety profile of enzalutamide.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Enzalutamide is an approved therapy for non-metastatic, castration-resistant prostate cancer on the basis of a lower risk for metastasis or death without radiographic progression. Furthermore, enzalutamide therapy is associated with a better quality of life and a lower risk of prostate specific antigen (PSA) progression. However, overall survival, which is an important end point and standard for regulatory approval, had not been reached for proper analysis by the end of the clinical trial. As such, this study analyzed the overall survival for enzalutamide therapy for non-metastatic, castration-resistant prostate cancer. The participants were randomized to receive enzalutamide or placebo-controlled treatment. The study determined the patients in the enzalutamide group had significantly longer medial overall survival compared to patients in the placebo-controlled group. Patients in the enzalutamide group experienced adverse events such as musculoskeletal events, cardiovascular events, and strokes at similar rates as previously reported.

This randomized trial was limited by the imaging modalities used in the study for disease diagnosis and monitoring patients’ conditions, as they were not the most sensitive techniques available for cancer detection of metastasis. Another limitation of the study was that data for time to progression for patients who received enzalutamide were not collected. Therefore, an evaluation could not be conducted on whether treatment with enzalutamide also translated to differences in treatment effect of subsequent therapies. Nonetheless, this study was strengthened by its long-term patient follow-up and matched patient characteristics between both groups. For physicians, the findings of this study highlight an additional treatment for patients with non-metastatic, castration-resistant prostate cancer.

Click to read the study in NEJM

Relevant Reading: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

RELATED REPORTS

PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]

#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

In-Depth [randomized controlled trial]: This randomized control trial enrolled 1401 patients in a multicenter study from 300 sites in 32 countries. Inclusion criteria included males who were 18 years of age or older, histologically confirmed adenocarcinoma of the prostate and ongoing androgen-deprivation therapy. The exclusion criteria for the study included history of cytotoxic chemotherapy, use of hormonal or biologic therapy for prostate cancer, and known or suspected brain metastasis. The patients were randomized to the enzalutamide or placebo-controlled treatment group in a 2:1 ratio. The primary outcome was overall survival. Overall survival was defined as the time from randomization to death from any cause. Additionally, adverse outcomes within both treatment groups were recorded. The median overall survival was significantly longer with enzalutamide treatment (67.0 months, 95% confidence interval [CI], 64.0 to not reached) compared to placebo-controlled treatment (56.3 months, 95% CI, 54.4 to 63.0). At the end of three years, 80% (95% CI, 77 to 83) of patients were alive in the enzalutamide group and 73% (95% CI, 69 to 77) of patients were alive in the placebo-controlled group. Enzalutamide in addition to androgen-deprivation therapy significantly lowered risk of death by 27% compared to the placebo group (hazard ratio, 0.73; 95% Ci, 0.61 to 0.89; P=0.001). Furthermore, serious adverse events occurred with steeper rate of initial onset in the enzalutamide group compared to the sorafenib group. The most common adverse event leading to death with enzalutamide treatment was cardiovascular events (2%), which was consistent with the known safety profile for enzalutamide. Taken together, administration of enzalutamide treatment plus androgen-deprivation therapy significantly increased median overall survival in patients with non-metastatic, castration-resistant prostate cancer.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: androgen deprivation therapy (ADT)chemotherapyenzalutamideprostate cancersorafenib
Previous Post

Kawasaki-like disease increase in Italian COVID-19 epicenter

Next Post

Congenital heart surgery may affect long-term social outcomes

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]

August 16, 2022
#VisualAbstract: Capivasertib in addition to fulvestrant improves  progression-free survival in ER⁺ advanced breast cancer
StudyGraphics

#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer

August 16, 2022
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

May 24, 2022
Next Post
Neurocognitive deficits in congenital heart disease may not worsen with age

Congenital heart surgery may affect long-term social outcomes

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Compression stockings do not add clinical benefit to pharmaco-thromboprophylaxis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Newborn screening for cystic fibrosis improves nutritional outcomes
  • BNT162b2 vaccine reduces rates of COVID-19 omicron variant infection in children
  • Non-contrast CT sensitive and specific for kidney stones [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.